View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 3, 2022

Boston Scientific reports 15.4% rise in Q4 2021 net sales

Boston Scientific achieved $11.888bn net sales for the full year 2021, representing 19.9% growth on reported basis.

Boston Scientific has reported net sales of $3.127bn in the fourth quarter (Q4) of 2021, representing a growth of 15.4% on a reported basis, 15.1% on an organic basis and 16.9% on an operational basis.

The net sales for the full year 2021 were $11.888bn, representing a 19.9% and 18.9% increase on a reported basis and organic basis, respectively.

Boston Scientific chairman and CEO Mike Mahoney said: “I’m very pleased with our strong fourth quarter and full-year results, thanks to our team’s commitment and resilience in a challenging environment.

“I’m excited about the capabilities we’ve built, and I remain confident in our ability to execute in 2022 and against our long-range plans as we continue delivering meaningful innovations for patients around the world.”

The company’s MedSurg segment achieved 12.1% reported basis, 13.3% operational basis and 9.4% organic basis growth in net sales, compared to the prior-year period.

The Cardiovascular segment reported a 25.3% and 27% net sales increase on reported basis and operational basis, respectively.

Meanwhile, the Rhythm and Neuro segment achieved a net sales increase of 11.8% on reported basis, 6.1% on organic basis and 13.2% on operational basis.

The company’s recent developments include the start of the MODULAR ATP clinical trial to assess the mCRM Modular Therapy System’s performance, safety and effectiveness.

Meanwhile, the purchase of WOLF Thrombectomy Platform developer Devoro Medical has been concluded.

Boston Scientific also initiated a limited market release of its AXIOS Stent in China. The device allows physicians to endoscopically manage symptomatic pseudocysts and walled-off pancreatic necrosis, the two most serious complications from pancreatitis.

Additionally, the company secured a higher-paying Ambulatory Payment Classification for its Rezūm Water Vapor Therapy from the US Centers for Medicare and Medicaid Services (CMS).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU